[DISCLOSURE] Pangen (222110) announced on Aug. 16 that it has signed a license agreement with Mexico’s Medicamentos Naturales on recombinant Factor VIII.

The agreement will give Medicamentos Naturales exclusive rights to marketing, commercializing, and sales without loyalty in Mexico as it pays for the US$1 million co-development process.